Quality of life in patients with immune-mediated inflammatory diseases

Journal of Rheumatology

Volumn 38, Issue SUPPL. 88, 2011, Pages 7-19

  Russell, Anthony S ^a,f,g,h   Gulliver, Wayne P ^b,f,g,h   Irvine, E Jan ^c,f,g,h   Albani, Salvatore ^d,f,g,h   Dutz, Jan P ^e,f,g,h  

^a UNIVERSITY OF ALBERTA   (Canada)

^b MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d BURNHAM INSTITUTE   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^g Eastern Health Canada   (Canada)

^h ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Inflammatory bowel diseases; Outcome assessment; Psoriasis; Psoriatic arthritis; Quality of life; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; INFLIXIMAB; MESALAZINE; METHOTREXATE; PLACEBO; RITUXIMAB;

COMBINATION CHEMOTHERAPY; COPING BEHAVIOR; COST UTILITY ANALYSIS; CROHN DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; ENTERITIS; ETHNOGRAPHY; FATIGUE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; IMMUNE MEDIATED INFLAMMATORY DISEASE; IMMUNOPATHOLOGY; LOW DRUG DOSE; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SHORT FORM 36; ULCERATIVE COLITIS; FEMALE; MALE; PSORIASIS; PSYCHOLOGICAL ASPECT; TREATMENT OUTCOME;

ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PSORIASIS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84855983482     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.110899     Document Type: Review

References (81)

1. Blumenauer B, Cranney A, Clinch J, Tugwell P. Quality of life in patients with rheumatoid arthritis: which drugs might make a difference? Pharmacoeconomics 2003;21:927-40. (Pubitemid 37222567)
2. Tugwell P, Idzerda L, Wells GA. Generic quality-of-life assessment in rheumatoid arthritis. Am J Manag Care 2007;13 Suppl 9:S224-S236.
3. Russak SM, Croft JD Jr, Furst DE, Hohlbauch A, Liang MH, Moreland L, et al Evidence-Based Medicine Working Groups in Rheumatology. The use of rheumatoid arthritis health-related quality of life patient questionnaires in clinical practice: lessons learned. Arthritis Rheum 2003;49:574-84. (Pubitemid 36988313)
4. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales. J Rheumatol 1982;9:789-93.
5. Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQOL (EQ-5D). Br J Rheumatol 1997;36:551-9.
6. Vaile JH, Mathers DM, Ramos-Remus C, Russell AS. Generic health instruments do not comprehensively capture patient perceived improvement in patients with carpal tunnel syndrome. J Rheumatol 1999;26:1163-6. (Pubitemid 29215084)
7. Russell AS, Conner-Spady B, Mintz A, Maksymowych WP. The responsiveness of generic health status measures as assessed in patients with rheumatoid arthritis receiving infliximab. J Rheumatol 2003;30:941-7. (Pubitemid 36529611)
8. Strand V, Crawford B, Singh J, Choy E, Smolen JS, Khanna D. Use of "spydergrams" to present and interpret SF-36 health-related quality of life data across rheumatic diseases. Ann Rheum Dis 2009;68:1800-4.
9. Kimel M, Cifaldi M, Chen N, Revicki D. Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA. J Rheumatol 2008;35:206-15. (Pubitemid 351284438)
10. Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care 2008;14:234-54.
11. Carr A, Hewlett S, Hughes R, Mitchell H, Ryan S, Carr M, et al. Rheumatology outcomes: the patient''s perspective. J Rheumatol 2003;30:880-3.
12. Kirwan J, Heiberg T, Hewlett S, Hughes R, Kvien T, Ahlmèn M, et al. Outcomes from the Patient Perspective Workshop at OMERACT 6. J Rheumatol 2003;30:868-72. (Pubitemid 36402790)
13. Kvien TK, Heiberg T. Patient perspective in outcome assessments - perceptions or something more? J Rheumatol 2003;30:873-6. (Pubitemid 36402791)
14. Hewlett SA. Patients and clinicians have different perspectives on outcomes in arthritis. J Rheumatol 2003;30:877-9. (Pubitemid 36402792)
15. Quest E, Aanerud GJ, Kaarud S, Collins S, Leong A, Smedeby B, et al. Patients' perspective. J Rheumatol 2003;30:884-5. (Pubitemid 36402794)
16. Kirwan JR, Ahlmén M, de Wit M, Heiberg T, Hehir M, Hewlett S, et al. Progress since OMERACT 6 on including patient perspective in rheumatoid arthritis outcome assessment. J Rheumatol 2005;32:2246-9. (Pubitemid 41587876)
17. Kirwan JR, Minnock P, Adebajo A, Bresnihan B, Choy E, de Wit M, et al. Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. J Rheumatol 2007;34:1174-7. (Pubitemid 46774870)
18. Kirwan JR, Hewlett SE, Heiberg T, Hughes RA, Carr M, Hehir M, et al. Incorporating the patient perspective into outcome assessment in rheumatoid arthritis - progress at OMERACT 7. J Rheumatol 2005;32:2250-6. (Pubitemid 41587877)
19. Russell AS, Wallenstein GV, Li T, Martin MC, Maclean R, Blaisdell B, et al. Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. Ann Rheum Dis 2007;66:189-94. (Pubitemid 46226053)
20. Mittendorf T, Dietz B, Sterz R, Kupper H, Cifaldi MA, von der Schulenburg JM. Improvement and longterm maintenance of quality of life during treatment with adalimumab in severe rheumatoid arthritis. J Rheumatol 2007;34:2343-50. (Pubitemid 350230654)
21. Rigby W, Ferraccioli G, Greenwald M, Zazueta-Montiel B, Fleischmann R, Wassenberg S, et al. Rituximab improved physical function and quality of life in patients with rheumatoid arthritis naive to methotrexate (IMAGE study). Arthritis Care Res 2011;63:711-20.
22. Kievit W, Adang EM, Fransen J, Kuper HH, van de Laar MA, Jansen TL, et al. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis 2008;67:1229-34.
23. Repping-Wuts H, van Riel P, van Achterberg T. Fatigue in patients with rheumatoid arthritis: what is known and what is needed. Rheumatology 2009;48:207-9.
24. Bergman MJ, Shahouri SS, Shaver TS, Anderson JD, Weidensaul DN, Busch RE, et al. Is fatigue an inflammatory variable in rheumatoid arthritis (RA)? Analyses of fatigue in RA, osteoarthritis, and fibromyalgia. J Rheumatol 2009;36:2788-94.
25. Wolfe F, Michaud K, Li T, Katz RS. EQ-5D and SF-36 quality of life measures in systemic lupus erythematosus: comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, and fibromyalgia. J Rheumatol 2010;37:296-304.
26. Wolfe F, Michaud K, Wallenstein G. Scale characteristics and mapping accuracy of the US EQ-5D, UK EQ-5D, and SF-6D in patients with rheumatoid arthritis. J Rheumatol 2010;37:1615-25.
27. Beresniak A, Russell AS, Haraoui B, Bessette L, Bombardier C, Duru G. Advantages and limitations of utility assessment methods in rheumatoid arthritis. J Rheumatol 2007;34:2193-200. (Pubitemid 350076878)
28. Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol 2001;15:16-7. (Pubitemid 32842766)
29. Mease PJ, Menter MA. Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol 2006;54:685-704.
30. Devrimci-Ozguven H, Kundakci TN, Kumbasar H, Boyvat A. The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients. J Eur Acad Dermatol Venereol 2000;14:267-71. (Pubitemid 32898918)
31. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-7. (Pubitemid 29418506)
32. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001;137:280-4. (Pubitemid 32240779)
33. Mahler R, Jackson C, Ijacu H. The burden of psoriasis and barriers to satisfactory care: results from a Canadian patient survey. J Cutan Med Surg 2009;13:283-93.
34. Wasel N, Poulin Y, Andrew R, Chan D, Fraquelli E, Papp K. A Canadian self-administered online survey to evaluate the impact of moderate-to-severe psoriasis among patients. J Cutan Med Surg 2009;13:294-302.
35. Lynde CW, Poulin Y, Guenther L, Jackson C. The burden of psoriasis in Canada: insights from the pSoriasis Knowledge IN Canada (SKIN) survey. J Cutan Med Surg 2009;13:235-52.
36. Dubertret L, Mrowietz U, Ranki A, van de Kerkhof PC, Chimenti S, Lotti T, et al EUROPSO Patient Survey Group. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 2006;155:729-36. (Pubitemid 44352553)
37. Krueger G, Feldman S, Camisa C, Duvic M, Elder JT, Gottlieb AB, et al. Two considerations for patients with psoriasis and their clinicians: What defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000;43:281-5. (Pubitemid 30626007)
38. Fortune DG, Richards HL, Kirby B, McElhone K, Markham T, Rogers S, et al. Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy. Arch Dermatol 2003;139:752-6. (Pubitemid 36705942)
39. Savage J. Ethnography and health care. BMJ 2000;321:1400-2.
40. Fortune DG, Main CJ, O'Sullivan TM, Griffiths CE. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br J Dermatol 1997;137:755-60. (Pubitemid 27496193)
41. Husted JA, Gladman DD, Cook RJ, Farewell VT. Responsiveness of health status instruments to changes in articular status and perceived health in patients with psoriatic arthritis. J Rheumatol 1998;25:2146-55. (Pubitemid 28505861)
42. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-6. (Pubitemid 24194579)
43. Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: What do Dermatology Life Quality Index scores mean? J Invest Dermatol 2005;125:659-64.
44. Finlay AY, Kelly SE. Psoriasis - an index of disability. Clin Exp Dermatol 1987;12:8-11. (Pubitemid 17223839)
45. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-22. (Pubitemid 37448924)
46. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, et al EXPRESS Study Investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366:1367-74. (Pubitemid 41443403)
47. Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled Phase III trial. J Am Acad Dermatol 2008;58:106-15. (Pubitemid 350298146)
48. Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008;158:558-66. (Pubitemid 351239154)
49. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72. (Pubitemid 38924405)
50. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89. (Pubitemid 41447111)
51. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum 2005;52:1227-36. (Pubitemid 40530131)
52. Reich K, Nestle FO, Papp K, Ortonne JP, Wu Y, Bala M, et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol 2006;154:1161-8. (Pubitemid 43727400)
53. Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL, et al. Impact of adalimumab treatment on patient-reported outcomes: Results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat 2007;18:341-50. (Pubitemid 350223202)
54. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al; PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675-84. (Pubitemid 351671884)
55. Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, et al. The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. J Am Acad Dermatol 2010;62:812-8.
56. Lim C, Brown P. Quality of life in psoriasis improves after standardized administration of narrowband UVB phototherapy. Australas J Dermatol 2006;47:37-40.
57. Touw CR, Hakkaart-Van Roijen L, Verboom P, Paul C, Rutten FF, Finlay AY. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. Br J Dermatol 2001;144:967-72.
58. van de Kerkhof PC. The impact of a two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet/Dovobet) on the quality of life in patients with psoriasis vulgaris: a randomized controlled trial. Br J Dermatol 2004;151:663-8.
59. Guyatt G, Mitchell A, Irvine EJ, Singer J, Williams N, Goodcare R, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989;96:804-10. (Pubitemid 19057603)
60. Drossman DA, Leserman J, Li ZM, Mitchell CM, Zagami EA, Patrick DL. The rating form of IBD patient concerns: a new measure of health status. Psychosom Med 1991;53:701-12.
61. Irvine EJ, Feagan BG, Wong CJ. Does self-administration of a quality of life index for inflammatory bowel disease change the results? J Clin Epidemiol 1996;49:1177-85. (Pubitemid 26348616)
62. Hlavaty T, Persoons P, Vermeire S, Ferrante M, Pierik M, Van Assche G, et al. Evaluation of short-term responsiveness and cutoff values of inflammatory bowel disease questionnaire in Crohn's disease. Inflamm Bowel Dis 2006;12:199-204.
63. Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, Löfberg R, Modigliani R, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002;122:512-30. (Pubitemid 34117002)
64. Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial. Am J Gastroenterol 1996;91:1571-8. (Pubitemid 26269173)
65. Alcala MJ, Casellas F, Fontanet G, Prieto L, Malagelada JR. Shortened questionnaire on quality of life for inflammatory bowel disease. Inflamm Bowel Dis 2004;10:383-91. (Pubitemid 39029181)
66. Cohen RD. The quality of life in patients with Crohn's disease. Aliment Pharmacol Ther 2002;16:1603-9.
67. Irvine EJ. Review article: Patients' fears and unmet needs in inflammatory bowel disease. Aliment Pharmacol Ther 2004;20:54-9. (Pubitemid 39319248)
68. Mussell M, Böcker U, Nagel N, Singer MV. Predictors of disease-related concerns and other aspects of health-related quality of life in outpatients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2004;16:1273-80. (Pubitemid 39627525)
69. Irvine EJ. Quality of life of patients with ulcerative colitis: past, present, and future. Inflamm Bowel Dis 2008;14:554-65. (Pubitemid 351571837)
70. Stjernman H, Tysk C, Almer S, Ström M, Hjortswang H. Worries and concerns in a large unselected cohort of patients with Crohn's disease. Scand J Gastroenterol 2010;45:696-706.
71. Nordin K, Påhlman L, Larsson K, Sundberg-Hjelm M, Lööf L. Health-related quality of life and psychological distress in a population-based sample of Swedish patients with inflammatory bowel disease. Scand J Gastroenterol 2002;37:450-7. (Pubitemid 34274330)
72. Graff LA, Walker JR, Clara I, Lix L, Miller N, Rogala L, et al. Stress coping, distress, and health perceptions in inflammatory bowel disease and community controls. Am J Gastroenterol 2009;104:2959-69.
73. Lix LM, Graff LA, Walker JR, Clara I, Rawsthorne P, Rogala L, et al. Longitudinal study of quality of life and psychological functioning for active, fluctuating, and inactive disease patterns in inflammatory bowel disease. Inflamm Bowel Dis 2008;14:1575-84.
74. Farrokhyar F, Marshall JK, Cawdron RA, Irvine EJ. Mood disorders (MD) worsen health related quality of life (HRQOL) in inflammatory bowel disease (IBD). Gastroenterol 2001;120:A451.
75. Irvine EJ, Yeh CH, Ramsey D, Stirling AL, Higgins PD. The effect of mesalazine therapy on quality of life in patients with mildly and moderately active ulcerative colitis. Aliment Pharmacol Ther 2008;28:1278-86.
76. Lichtenstein GR, Bala M, Han C, DeWoody K, Schaible T. Infliximab improves quality of life in patients with Crohn's disease. Inflamm Bowel Dis 2002;8:237-43. (Pubitemid 34784975)
77. Feagan BG, Yan S, Bala M, Bao W, Lichtenstein GR. The effects of infliximab maintenance therapy on health-related quality of life. Am J Gastroenterol 2003;98:2232-8. (Pubitemid 37305364)
78. Loftus EV, Feagan BG, Colombel JF, Rubin DT, Wu EQ, Yu AP, et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol 2008;103:3132-41.
79. Feagan BG, Coteur G, Tan S, Keininger DL, Schreiber S. Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease. Am J Gastroenterol 2009;104:1976-83.
80. Reinisch W, Sandborn WJ, Bala M, Yan S, Feagan BG, Rutgeerts P, et al. Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. Inflamm Bowel Dis 2007;13:1135-40. (Pubitemid 47402598)
81. Hanauer SB, Uma Mahadevan-Velayos U, Panaccione R. Advances in biologic therapy for inflammatory bowel disease - the evolving treatment paradigm. [Internet. Accessed August 2, 2011.] Available from: http://www.medscape.org/ viewarticle/587175